![Bali Muralidhar](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bali Muralidhar
Directeur en chef des Investissements chez
Abingworth LLP
Fortune : 140 $ au 31/03/2024
Profil
Bali Muralidhar is currently Director at Gynesonics, Inc., Dassiet Oy, Stryve Online Ltd., Ascend Advanced Therapies Ltd. (since 2023), Launch Therapeutics, Inc. (since 2022), Cytospire Therapeutics Ltd. (since 2023), and Global Head of Life Sciences & CIO at Abingworth LLP (since 2019).
Former roles include Director at ZipLine Medical, Inc., Exicure Operating Co., Wugen, Inc., Anjarium Biosciences AG, Glycomine, Inc., and NuCana Plc (Independent Non-Executive Director); Independent Director at Wilson Therapeutics AB (2014–2018), Exicure, Inc. (2019–2022), Reneo Pharmaceuticals, Inc. (2021–2024), and Spruce Biosciences, Inc. (2020–2025); Member-Healthcare Deal Department at Bain Capital LP (2011–2012); Senior Partner at MVM Partners LLP (2012–2019); and Member-Supervisory Board at Valneva SE (2017–2019).
Education includes doctorates from the University of Oxford and the University of Cambridge.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/04/2025 | 540 ( 0% ) | 140 $ | 31/03/2024 | |
| 22/07/2025 | 0 ( -.--% ) | - $ | 31/07/2026 |
Postes actifs de Bali Muralidhar
| Sociétés | Poste | Début |
|---|---|---|
Dassiet Oy
 Dassiet Oy Medical SpecialtiesHealth Technology Develops and markets products for orthopedic and traumatology use | Directeur/Membre du Conseil | - |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Directeur en chef des Investissements | 01/08/2022 |
Stryve Online Ltd.
 Stryve Online Ltd. Miscellaneous Commercial ServicesCommercial Services Provides human resources services | Directeur/Membre du Conseil | - |
Gynesonics, Inc.
 Gynesonics, Inc. Medical SpecialtiesHealth Technology Develops medical devices for diagnostic intrauterine imaging and trans cervical treatment of symptomatic uterine fibroids | Directeur/Membre du Conseil | - |
Launch Therapeutics, Inc.
 Launch Therapeutics, Inc. Financial ConglomeratesFinance Provides investment and therapies development services | Directeur/Membre du Conseil | 01/04/2022 |
Ascend Gene & Cell Therapies Ltd.
 Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology research and development center | Directeur/Membre du Conseil | 01/02/2023 |
Anciens postes connus de Bali Muralidhar
| Sociétés | Poste | Fin |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Directeur/Membre du Conseil | 15/10/2025 |
| ONKURE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/10/2024 |
| EXICURE, INC. | Directeur/Membre du Conseil | 30/12/2022 |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Bali Muralidhar
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
65
Relations au 1er degré
21
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 21 |
|---|---|
Gynesonics, Inc.
Gynesonics, Inc. Medical SpecialtiesHealth Technology Develops medical devices for diagnostic intrauterine imaging and trans cervical treatment of symptomatic uterine fibroids | Health Technology |
ZipLine Medical, Inc.
 ZipLine Medical, Inc. Medical SpecialtiesHealth Technology Develops non-invasive surgical skin closure devices | Health Technology |
Bain Capital LP
 Bain Capital LP Financial ConglomeratesFinance Provides investment services | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Finance |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MVM Partners LLP
 MVM Partners LLP Investment ManagersFinance MVM Partners invests in companies located across the globe. The firm targets companies operating in the fields of healthcare and life sciences sectors. It provides financing for growth capital requirements with an investment size of USD 20 - 100 million. | Finance |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dassiet Oy
Dassiet Oy Medical SpecialtiesHealth Technology Develops and markets products for orthopedic and traumatology use | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Exicure Operating Co.
 Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Develops immunomodulatory and gene regulating drugs | Health Technology |
Valneva SE
 Valneva SE BiotechnologyHealth Technology Develops and commercializes of prophylactic vaccines for infectious diseases | Health Technology |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company focusing in treatment of Wilson disease | Health Technology |
Reneo Pharmaceuticals, Inc.
 Reneo Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases | Health Technology |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Develops replacement therapies for rare genetic diseases | Health Technology |
Exicure, Inc.
 Exicure, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops nucleic acid therapies against to neurological disorders and hair loss | Health Technology |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Develops CAR-T therapy platform for cancer therapies | Technology Services |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Develops non-viral gene therapy | Health Technology |
Stryve Online Ltd.
Stryve Online Ltd. Miscellaneous Commercial ServicesCommercial Services Provides human resources services | Commercial Services |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology research and development center | Commercial Services |
Launch Therapeutics, Inc.
Launch Therapeutics, Inc. Financial ConglomeratesFinance Provides investment and therapies development services | Finance |
